Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 18.75p 18.50p 19.00p 18.75p 18.75p 18.75p 196,008 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.4 -23.2 -10.4 - 40.66

Amryt Pharma Share Discussion Threads

Showing 3251 to 3271 of 3275 messages
Chat Pages: 131  130  129  128  127  126  125  124  123  122  121  120  Older
DateSubjectAuthorDiscuss
10/8/2018
23:42
Couple of AMYT charts. First one shows that the 20 day EMA has recently gone above the 50 day EMA. The first time this has happened since before last September's placing destroyed the share price See the arrows. free stock charts from uk.advfn.com The second one shows that the AMYT share price has recently broken out from a downtrend that has lasted since before Christmas when there was a recovery in the share price based on the Midas tip in the Mail. That breakout above the upper downtrend line has been retested. free stock charts from uk.advfn.com
papillon
07/8/2018
12:36
Back to normal for AMYT. You can buy below the mid price so your buy will show as a sell on advfn, lse, etc.
papillon
06/8/2018
14:41
I'll definitely continue to hold AMYT until the interim analysis is released in Q4 2018, bazworth. After that, who knows?
papillon
04/8/2018
20:44
Best not to think about it!! It would appear that the ‘Boys and Girls’ at AMRYT at doing all that we could hope of them! V happy to hold for a good while longer!!
bazworth
04/8/2018
19:08
I dread to think what the AMYT share price would be now without the Lojuxta licensing deal. Half what it is now? Definitely below 10p.
papillon
03/8/2018
11:24
It's an interim analysis. That's what it says in the RNS's. From the RNS dated 19th July: "Moving to Amryt's late stage development pipeline, the investigational global Phase III ('EASE') clinical trial with AP101 for Epidermolysis bullosa ("EB") is progressing well with a pre-planned interim efficacy analysis expected to be completed in Q4 2018, and top-line data expected in Q2 2019. It is estimated that the market potential for AP101 is more than EUR1 billion." PS. It says the "interim efficacy analysis" is expected to be completed in Q4 2018. The company seem to have dropped the "early Q4"
papillon
02/8/2018
22:06
Correct! I’ve been waiting bl@@dy ages!
bazworth
02/8/2018
22:06
Correct! I’ve been waiting bl@@dy ages!
bazworth
02/8/2018
22:04
Haha....I love that word 'whoosh'......it equates to money in the bank! 😁
greendragon777
02/8/2018
21:55
Will we get an anticipatory whoosh before Nov? I reckon we will....!
bazworth
02/8/2018
21:55
Will we get an anticipatory whoosh before Nov? I reckon we will....!
bazworth
02/8/2018
20:54
I didn't notice that Alphabravo, I haven't been keeping an eye on the detail. However I think I recall the initial interim date of Q1 this year changed to H1 over the course of 2017 so I guess these dates tend to slip a bit over time for whatever reason. My guess is it will probably come some time in November but that's just a pure guess. The clock is ticking down fast though so it will be upon us in no time! 😃
greendragon777
02/8/2018
20:38
Anyone else note how the interim readout is now "later this year" as opposed to the previous "early in Q4"?....Too much time on my hands
alphabravo321
02/8/2018
18:29
Fingers crossed we'll be half way there in a couple of months time. All roads lead to AP101......😀
greendragon777
02/8/2018
17:27
Yes, it will add GREATLY to the upside, waterloo, but only when AP101 receives regulatory approval for EB.
papillon
02/8/2018
16:23
Yes but on approval it now has a minimum guaranteed $100m/$150m + upside.
waterloo01
02/8/2018
11:03
Will the AMYT share price retest the next resistance level @ 20.3p in the next week, or so, without more good news? Got my doubts! Whilst today's news is good, as waterloo01 states, this rare desease designation is only of any value if AP101 gets approval. Everything, as before, depends on whether the EASE trial is successful, or not.
papillon
02/8/2018
10:42
Have to say getting a priority review voucher is quite a coup, especially so late in the cycle. Naturally only worth something if AP101 gets approved but instantly increases it's value significantly. Added today.
waterloo01
02/8/2018
07:29
Fantastic.
bermudashorts
02/8/2018
07:12
Excellent news. These sell for over $150m if AP101 gets approved
waterloo01
01/8/2018
12:29
Yes you could well be correct, diamondstar, on H2 2018 cash burn being lower than H1 2018. Let's hope so. You have far more insight on costs than the rest of us, diamondstar, because of your extensive biopharma experience and knowledge. IMO the most important driver of the AMYT share price will be the EASE trial results. The EASE phase III trial is why I'm invested in AMYT. EDIT: Well the Ichimoku chart has recently turned Strongly Bullish on AMYT (visit ichimokutrader.com to see their AMYT chart). It wouldn't surprise me to see the AMYT share price start to slowly rise from the current 18.375p as we get closer to the interim results (expected early September) and the EASE interim update (expected early October)
papillon
Chat Pages: 131  130  129  128  127  126  125  124  123  122  121  120  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180814 11:24:37